References
- Alexenko A.P., Ealy A.D., Roberts R.M.: The cross-species antiviral activities of different IFN-tau subtypes on bovine, murine, and human cells: contradictory evidence for therapeutic potential. J Interferon Cytokine Res 1999, 19, 1335–1341, doi: 10.1089/107999099312795.
- Armstrong J.A.: Cytopathic effect inhibition assay for interferon: microculture plate assay. Methods Enzymol 1981, 78, 381–387, doi: 10.1016/0076-6879(81)78145-x.
- Commission of Chinese Veterinary Pharmacopoeia:. Veterinary Pharmacopeia of the People’s Republic of China, 2010 edition. China Agriculture Press, Beijing. 2010, Part I, Appendix 26–130.
- Demmers K.J., Derecka K., Flint A.: Trophoblast interferon and pregnancy. Reproduction 2001, 121, 41–49, doi: 10.1530/rep.0.1210041.
- Isaacs A., Lindenmann J.: Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957, 147, 258–267, doi: 10.1098/rspb.1957.0048.
- Jeannin P., Duluc D., Delneste Y.: IL-6 and leukemia-inhibitory factor are involved in the generation of tumor-associated macrophage: regulation by IFN-gamma. Immunother 2011, 3, 23–26, doi: 10.2217/imt.11.30.
- Johnson J.A., Hochkeppel H.K., Gangemi J.D.: IFN-tau exhibits potent suppression of human papillomavirus E6/E7 oncoprotein expression. J Interferon Cytokine Res 1999, 19, 1107–1116.
- Juste R.A., Ott T.L., Kwang J., Bazer F.W., de la Concha-Bermejillo A.: Effects of recombinant ovine interferon-tau on ovine lentivirus replication and progression of disease. J Gen Virol 2000, 81, 525–532, doi: 10.1099/0022-1317-81-2-525.
- Khan O.A., Jiang H., Subramanian P.S., Johnson H.M., Dhib-Jalbut S.S.: Immunomodulating functions of recombinant ovine interferon tau: potential for therapy in multiple sclerosis and autoimmune disorders. Mult Scler 1998, 4, 63–69, doi: 10.1177/135245859800400204.
- Kruger N.J.: The Bradford method for protein quantitation. In: Basic Protein and Peptide Protocols, part of Methods in Molecular Biology vol. 32, edited by J.M. Walker, Humana, Totowa, NJ, 1994, pp. 9–15, doi: 10.1385/0-89603-268-X:9.
- Martal J.L., Chêne N.M., Huynh L.P., L’Haridon R.M., Reinaud P.B., Guillomot M.W., Charlier M.A., Charpigny S.Y.: IFN-tau: a novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Biochimie 1998, 80, 755–777, doi: 10.1016/s0300-9084(99)80029-7.
- Ott T.L., Van Heeke G., Johnson H.M., Bazer F.W.: Cloning and expression in Saccharomyces cerevisiae of a synthetic gene for the type-I trophoblast interferon ovine trophoblast protein-1: purification and antiviral activity. J Interferon Res 1991, 11, 357–364, doi: 10.1089/jir.1991.11.357.
- Pestka S., Krause C.D., Walter M.R.: Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004, 202, 8–32, doi: 10.1111/j.0105-2896.2004.00204.x.
- Pitha P.M., Kunzi M.S.: Type I interferon: The ever unfolding story. Curr Top Microbiol 2007, 316, 41–70, doi: 10.1007/978-3540-71329-6_4.
- Pontzer C.H., Yamamoto J.K., Bazer F.W., Ott T.L., Johnson H.M.: Potent anti-feline immunodeficiency virus and anti-human immunodeficiency virus effect of IFN-tau. J Immunol 1997, 158, 4351–4357.
- Reed L.J., Muench H.: A simple method of estimating 50 percent end points. Am J Hyg 1938, 27, 493–497, doi: 10.1093/oxfordjournals.aje.a118408.
- Rogez C., Martin M., Dereuddre-Bosquet N., Martal J., Dormont D., Clayette P.: Anti-human immunodeficiency virus activity of tau interferon in human macrophages: involvement of cellular factors and beta-chemokines. J Virol 2003, 77, 12914–12920, doi: 10.1128/JVI.77.23.12914-12920.2003.
- Rubinstein S., Familletti P.C., Pestka S.: Convenient assay for interferons. J Virol 1981, 37, 755–758, doi: 10.1128/JVI.37.2.755-758.1981.
- Samuel C.E.: Antiviral actions of interferons. Clin Microbiol Rev 2001, 14, 778–809, doi: 10.1128/CMR.14.4.778-809.2001.
- Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., Kuestner R., Garrigues U., Birks C., Roraback J., Ostrander C., Dong D., Shin J., Presnell S., Fox B., Haldeman B., Cooper E., Taft D., Gilbert T., Grant F.J., Tackett M., Krivan W., McKnight G., Clegg C., Foster D., Klucher K.M.: IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003, 4, 63–68, doi: 10.1038/ni873.
- Sinha J., Plantz B.A., Zhang W., Gouthro M., Schlegel V., Liu C.P., Meagher M.M.: Improved production of recombinant ovine interferon-tau by mut(+) strain of Pichia pastoris using an optimized methanol feed profile. Biotechnol Prog 2003, 19, 794–802, doi: 10.1021/bp025744q.
- Soos J.M., Johnson H.M.: Interferon-tau: prospects for clinical use in autoimmune disorders. BioDrugs 1999, 11, 125–135, doi: 10.2165/00063030-199911020-00006.
- Taylor K.E., Mossman K.L.: Recent advances in understanding viral evasion of type I interferon. Immunology 2013, 138, 190–197, doi: 10.1111/imm.12038.
- Tian L., Zhao P., Ma B., Guo G., Sun Y., Xing M-W.: Cloning, expression and antiviral bioactivity of red-crowned crane interferon-alpha. Gene 2014, 544, 49–55, doi: 10.1016/j.gene.2014.04.036.
- Todt D., Francois C., Anggakusuma., Behrendt P., Engelmann M., Knegendorf L., Vieyres G., Wedemeyer H., Hartmann R., Pietschmann T., Duverlie G., Steinmann E.: Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication. Antimicrob Agents Chemother 2016, 60, 2132–2139, doi: 10.1128/aac.02427-15.
- Usharani J., Park S.Y., Cho E-J., Kim C., Ko Y-J., Tark D., Kim S-M., Park J-H., Lee K-N., Lee M-H., Lee H-S.: Antiviral activity of ovine interferon tau 4 against foot-and-mouth disease virus. Antiviral Res 2017, 143, 134–141, doi: 10.1016/j.antiviral.2017.01.018.
- Van Heeke G., Ott T.L., Strauss A., Ammaturo D., Bazer F.W.: High yield expression and secretion of the ovine pregnancy recognition hormone interferon-tau by Pichia pastoris. J Interferon Cytokine Res 1996, 16, 119–126, doi: 10.1089/jir.1996.16.119.